Sutro Biopharma (STRO) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Study Overview: Sutro Biopharma is conducting a Phase 1 open-label study titled A Phase 1 Open-Label Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-Tumor Activity of STRO-004 in Adults With Refractory/Recurrent Metastatic Solid Tumors. The study aims to assess the safety and preliminary anti-tumor activity of STRO-004 in adults with various metastatic cancers, which is crucial for developing new cancer treatments.
Intervention/Treatment: The study tests STRO-004, an experimental drug administered via IV infusion, both as a monotherapy and in combination with Pembrolizumab, another IV infusion drug. These interventions aim to evaluate their effectiveness in treating metastatic cancers.
Study Design: This interventional study is non-randomized with a sequential intervention model. It is open-label, meaning no masking is involved, and its primary purpose is treatment-focused.
Study Timeline: The study began on November 7, 2025, with its latest update submitted on December 1, 2025. These dates are important as they indicate the study’s current recruiting status and recent developments.
Market Implications: The progress of this study could positively influence Sutro Biopharma’s stock performance and investor sentiment, given the potential breakthrough in cancer treatment. Competitors in the oncology sector may also be impacted as they monitor the outcomes of STRO-004’s efficacy and safety.
The study is ongoing, and further details are available on the ClinicalTrials portal.
To learn more about STRO’s potential, visit the Sutro Biopharma drug pipeline page.